Menu

August 25, 2022

News
Media
Awards
Contact
News
Media Resources
Awards
Contact
August 25, 2022
Highlights of Asieris 2022 Semi-Annual Report

2026

2025

2024

2023

2022

2021

2020

2019

August 25, 2022
Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
April 17, 2026
Asieris Pharmaceuticals Releases 2025 Annual Report：Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growth
August 25, 2022
Highlights of Asieris 2022 Semi-Annual Report
August 25, 2022
Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
March 3, 2026
Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
August 25, 2022
Highlights of Asieris 2022 Semi-Annual Report
August 25, 2022
Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
January 8, 2026
Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors
August 25, 2022
Highlights of Asieris 2022 Semi-Annual Report